Delving into the Latest Updates on GIRK1/4 inhibitor (Novartis) with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms-

Target

Kir3.1 x Kir3.4

Action

inhibitors

Mechanism

Kir3.1 inhibitors(KCNJ potassium channel-3 inhibitors), Kir3.4 inhibitors(KCNJ potassium channel-5 inhibitors)

Therapeutic Areas

Cardiovascular Diseases

Active Indication

Atrial Fibrillation

Inactive Indication-

Originator Organization

Novartis Institutes for Biomedical Research, Inc.

Active Organization

Novartis Institutes for Biomedical Research, Inc.

Inactive Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

Atrial fibrillation (AF) is the most common cardiac arrhythmia, and a significant risk factor for ischemic stroke and heart failure. Marketed anti-arrhythmic drugs can restore sinus rhythm, but with limited efficacy and significant toxicities, including potential to induce ventricular arrhythmia. Atrial-selective ion channel drugs are expected to restore and maintain sinus rhythm without risk of ventricular arrhythmia. One such atrial-selective channel target is GIRK1/4 (G-protein regulated inwardly rectifying potassium channel 1/4). Here we describe 14b, a potent GIRK1/4 inhibitor developed to cardiovert AF to sinus rhythm while minimizing central nervous system exposure - an issue with preceding GIRK1/4 clinical candidates.

100 Deals associated with GIRK1/4 inhibitor (Novartis)

Login to view more data